This section is about breaking down the clinical data. I think the hardest part of being a biotechnology investor is knowing how to read the clinical data, and how to figure out what it all means. There are a lot of technical endpoints that can confuse investors. Sometimes companies fail to design a good clinical trial. This happens too often. Many of these young companies are not experts in designing or running clinical trials. This section is about teaching you how to read clinical trials and what data to look for, but a lot of it will be going through actual clinical data readouts by companies and breaking it down. I am not an expert in reading clinical data, but I have been doing it for many years. Most of the takes I give on clinical data will be just my point of view.
* I am not a doctor. This is not designed to be Medical Advice. Please refer to your doctor for Medical Decisions